Name | Title | Contact Details |
---|
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
Protoms Radiance 330 Proton Therapy System is compact, customizable, and has the industrys fastest return on investment.
Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.
Opiant Pharmaceuticals` team of industry and addiction experts are dedicated developing treatments for addiction, overdose, and related disorders for the mass market. Our first product NARCAN® Nasal Spray became available in the United States and Canada through our commercial partner, Adapt Pharma.